Analysis on the Epidemiological Characteristics of Breakthrough Varicella Cases and Incremental Effectiveness of 2-Dose Varicella Vaccine in China.

IF 5.2 3区医学 Q1 IMMUNOLOGY

Vaccines Pub Date : 2025-02-06 DOI:10.3390/vaccines13020160

Mingzhu Lin, Tian Yang, Pengfei Deng, Laibao Yang, Caoyi Xue

{"title":"Analysis on the Epidemiological Characteristics of Breakthrough Varicella Cases and Incremental Effectiveness of 2-Dose Varicella Vaccine in China.","authors":"Mingzhu Lin, Tian Yang, Pengfei Deng, Laibao Yang, Caoyi Xue","doi":"10.3390/vaccines13020160","DOIUrl":null,"url":null,"abstract":"Background: A 2-dose varicella vaccination strategy has been implemented in Shanghai, China since 2018. This study aims to analyze the epidemiological characteristics of breakthrough varicella cases and to evaluate the incremental effectiveness of the 2-dose varicella vaccination among Chinese children.Methods: A retrospective investigation was conducted among native children born between 2015 and 2019 in the Pudong New area of Shanghai, China. From 2016 to 2023, demographic information and data regarding varicella vaccination were collected through the Shanghai Immunization Information System, while information on varicella infections was obtained from the China Information System for Disease Control and Prevention. The incremental vaccine effectiveness (VE) for varicella was defined as (1 - relative risk (RR)) × 100%, where RRs were calculated based on the rate of varicella infections.Results: A total of 519,951 local children were enrolled in the cohort analysis. The overall rate of breakthrough varicella infections was found to be 0.25%, corresponding to 1182 cases. Specifically, the rates of breakthrough varicella infections for individuals who received 1-dose and 2-dose VarV were 0.39% (977 cases) and 0.10% (205 cases), respectively. The average ages of onset for these infections were 2.13 ± 0.99 years and 5.52 ± 1.18 years, respectively. Furthermore, the breakthrough varicella infection rate among individuals born between 2015 and 2019 exhibited a decline, decreasing from 0.52% to 0.26% for those who received one dose of VarV, and from 0.23% to 0.01% for those who received two doses. The VE against all varicella was 85% (95% confidence interval: 84-86) for one dose and 96% (95% confidence interval: 96-97) for two doses, and the incremental VE was 75% (95% confidence interval: 71-79) compared with 1-dose.Conclusions: the 2-dose VarV vaccination strategy provided excellent protection to prevent varicella, and the universal 2-dose regimen of the varicella vaccine should be recommended to prevent varicella disease among children in China.","PeriodicalId":23634,"journal":{"name":"Vaccines","volume":"13 2","pages":""},"PeriodicalIF":5.2000,"publicationDate":"2025-02-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11860291/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccines","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3390/vaccines13020160","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: A 2-dose varicella vaccination strategy has been implemented in Shanghai, China since 2018. This study aims to analyze the epidemiological characteristics of breakthrough varicella cases and to evaluate the incremental effectiveness of the 2-dose varicella vaccination among Chinese children.

Methods: A retrospective investigation was conducted among native children born between 2015 and 2019 in the Pudong New area of Shanghai, China. From 2016 to 2023, demographic information and data regarding varicella vaccination were collected through the Shanghai Immunization Information System, while information on varicella infections was obtained from the China Information System for Disease Control and Prevention. The incremental vaccine effectiveness (VE) for varicella was defined as (1 - relative risk (RR)) × 100%, where RRs were calculated based on the rate of varicella infections.

Results: A total of 519,951 local children were enrolled in the cohort analysis. The overall rate of breakthrough varicella infections was found to be 0.25%, corresponding to 1182 cases. Specifically, the rates of breakthrough varicella infections for individuals who received 1-dose and 2-dose VarV were 0.39% (977 cases) and 0.10% (205 cases), respectively. The average ages of onset for these infections were 2.13 ± 0.99 years and 5.52 ± 1.18 years, respectively. Furthermore, the breakthrough varicella infection rate among individuals born between 2015 and 2019 exhibited a decline, decreasing from 0.52% to 0.26% for those who received one dose of VarV, and from 0.23% to 0.01% for those who received two doses. The VE against all varicella was 85% (95% confidence interval: 84-86) for one dose and 96% (95% confidence interval: 96-97) for two doses, and the incremental VE was 75% (95% confidence interval: 71-79) compared with 1-dose.

Conclusions: the 2-dose VarV vaccination strategy provided excellent protection to prevent varicella, and the universal 2-dose regimen of the varicella vaccine should be recommended to prevent varicella disease among children in China.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Vaccines Pharmacology, Toxicology and Pharmaceutics-Pharmacology

CiteScore

8.90

自引率

16.70%

发文量

1853

审稿时长

18.06 days

期刊介绍： Vaccines (ISSN 2076-393X) is an international, peer-reviewed open access journal focused on laboratory and clinical vaccine research, utilization and immunization. Vaccines publishes high quality reviews, regular research papers, communications and case reports.